Market intelligence workspace
Market intelligence workspace
PFSA is under heavy pressure, with the stock down sharply even as the latest earnings update was inline and recent news included a positive CE Mark review step for its Lumee Oxygen Platform. The wider picture is mixed to bearish: there is no notable options activity right now, institutional filings are split, and the next confirmed earnings date is November 18.
Generated Aug 21, 2026Profusa, Inc. Common Stock
Updated Aug 21, 5:55 AM UTCReported EPS compared with analyst estimates.
Reported EPS history is not available for this ticker.
Free market coverage from the current news feed.
Profusa has submitted a comprehensive response package to its European Notified Body GMED following successful completion of Stage 1 and Stage 2 assessments for CE Mark certification of its Lumee Oxygen Platform. The submission includes updates to technical documentation, quality system evidence, clinical evaluation activities, and validation information. The company remains committed to obtaining CE Mark certification to support European commercialization of its tissue oxygen monitoring technology.
Read storyProfusa, Inc. (PFSA) has been granted approval by the Nasdaq Hearings Panel to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market. The company must satisfy interim milestones and comply with bid price and stockholders' equity requirements by July 6, 2026, to maintain its continued listing.
Read storyProfusa (NASDAQ: PFSA) shares plummeted 40.27% on Tuesday following the announcement of a Letter of Intent to acquire BioInsights' PanOmics multi-omics diagnostics platform for approximately $30 million in an all-equity deal. The acquisition marks Profusa's strategic expansion into molecular diagnostics and aims to complement its Lumee real-time biochemistry monitoring system, with initial commercialization targeting pancreatic cancer.
Read storyProfusa announced an all-equity acquisition of BioInsights LLC's PanOmics multi-omics diagnostics platform, expanding into precision diagnostics. The deal adds $30 million to shareholder equity and accelerates commercialization through integration with Profusa's Lumee platform. The company is also advancing a Mayo Clinic collaboration for pancreatic cancer applications. Profusa shares surged 134.99% in premarket trading.
Read storyProfusa announced a new distributor partnership with MedSell in France to commercialize its Lumee Oxygen tissue monitoring device for critical limb threatening ischemia (CLTI) patients. This partnership, combined with existing distributors across Europe, now covers approximately 200,000 annual CLI cases in the EU. The company projects $0.5-$2 million revenue in 2026 and $9-$13 million in 2027, with plans to reach $200-$250 million by 2030.
Read storyProfusa completed a merger with NorthView Acquisition Corporation, reduced net debt to $14 million, and is preparing to launch its Lumee Oxygen tissue monitoring platform in Europe in early 2026, with potential revenue targets of $0.5-$2 million in 2026 and $9-$13 million in 2027.
Read storyCore valuation, range, and trading metrics.
Recent disclosed activity connected to public officials.
Premium crowd and conversation intelligence.
Notable contracts and premium concentration.
Large institutional position updates.